The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Roche has formally entered into a definitive agreement to acquire specific components of the LumiraDx group NASDAQ GS LMDX related to LumiraDxs Point of Care technology
Nectin Therapeutics Ltd a biotechnology company focusing on the development of targeted immunotherapies to overcome resistance to approved immune oncology treatments has made notable progress in its Phase clinical trial
Bracco Imaging SpA has obtained marketing approval from the European Commission for Vueway a new contrast agent for magnetic resonance imaging The approval backed by the Committee
Ono Pharmaceutical Co Ltd recently announced a collaborative agreement with EVQLV INC The collaboration is focused on the development of innovative antibody drugs through the generation of novel antibodies
NS Pharma Inc a subsidiary of Nippon Shinyaku Co Ltd has been granted orphan drug designation by the European Commission for NSNCNP on December This drug is currently in development
Rentschler Biopharma SE a leading global contract development and manufacturing organization specializing in biopharmaceuticals has revealed a significant development for its newly established Rentschler Biopharma Manufacturing Center
Neuraxpharm Group a leading European pharmaceutical company specializing in the treatment of central nervous system disorders has been informed by the European Commission that it will revoke all centrally granted
Infinimmune a biotechnology company specializing in novel methods for antibody drug discovery and development has recently entered into a collaboration with Grid Therapeutics a clinicalstage biotechnology
In a recent collaborative venture InxMed a clinicalstage biotechnology firm specializing in groundbreaking therapies for drug resistance and Escugen a clinicalstage antibodydrug conjugate
Charles River Laboratories International Inc has reached a significant milestone in its collaboration with Vertex Pharmaceuticals by obtaining regulatory approval for the production of CASGEVY
